Key result
Above-median IgM anti-PC linked to ~40% lower cardiovascular risk in early rheumatoid arthritis.
Why the study?
Increased cardiovascular risk in rheumatoid arthritis is not fully explained by traditional risk factors, and IgM anti-phosphorylcholine antibodies may have atheroprotective effects.
Do higher baseline levels of IgM anti-PC antibodies predict a lower risk of incident cardiovascular events in patients with early rheumatoid arthritis?
Population
653 early RA patients without prevalent CVD from the BARFOT cohort
Comparison
Baseline IgM anti-PC levels above median vs below median
Design
Cohort study
Follow-up
Mean 11.7 years
Authors
Loading...
Does not support routine IgM anti-PC testing in early RA; leaves open prospective validation as a cardiovascular biomarker.
Cohort (n=653)
Do higher baseline levels of IgM anti-PC antibodies predict a lower risk of incident cardiovascular events in patients with early rheumatoid arthritis?
Effect estimate: HR 0.603 (95% CI 0.430-0.846)
p-value: p=0.003
Higher levels of innate IgM anti-PC autoantibodies are associated with a lower risk of incident cardiovascular events in specific high-risk subgroups of patients with early rheumatoid arthritis.
Ajeganova et al. (2021) conducted a cohort in Early rheumatoid arthritis (n=653). Baseline IgM anti-PC above median vs. Baseline IgM anti-PC below median was evaluated on Incident cardiovascular events (HR 0.603, 95% CI 0.430-0.846, p=0.003). Baseline IgM anti-PC levels above the median were associated with a 40% reduction in the risk of incident cardiovascular events compared to levels below the median in patients with early rheumatoid arthritis.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: